Form 8-K - Current report:
SEC Accession No. 0001193125-25-158719
Filing Date
2025-07-14
Accepted
2025-07-14 16:03:33
Documents
13
Period of Report
2025-07-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d63996d8k.htm   iXBRL 8-K 24892
2 EX-99.1 d63996dex991.htm EX-99.1 15208
  Complete submission text file 0001193125-25-158719.txt   159899

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atra-20250714.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20250714_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20250714_pre.xml EX-101.PRE 11264
15 EXTRACTED XBRL INSTANCE DOCUMENT d63996d8k_htm.xml XML 3656
Mailing Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320
Business Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320 805-623-4211
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 251121768
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)